Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based ...
Y es, Parkinson's is a disease that effects nerve cells in the brain, leading to tremors, stiffness, speech changes and more, ...
Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...
Researchers develop 3D blood-brain barrier model to study Alzheimers and neuroinflammation New platform created to improve ...
Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that the U.S. Food and Drug Administration ...
Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...
Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...
Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback